MX2021012608A - Nuevas moleculas para terapia y diagnostico. - Google Patents

Nuevas moleculas para terapia y diagnostico.

Info

Publication number
MX2021012608A
MX2021012608A MX2021012608A MX2021012608A MX2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A MX 2021012608 A MX2021012608 A MX 2021012608A
Authority
MX
Mexico
Prior art keywords
disease
synuclein
dementia
lewy
syn
Prior art date
Application number
MX2021012608A
Other languages
English (en)
Inventor
John Warner
Elpida Tsika
Romain Christian Ollier
Jan Peter Henning Stöhr
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2021012608A publication Critical patent/MX2021012608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas novedosas que pueden emplearse para la prevención, alivio tratamiento y/o diagnóstico de enfermedades, trastornos y anomalías asociadas con agregados de alfa-sinucleína (a-sinucleína, A-sinucleína, aSinucleína, A-syn, a-syn, aSyn, a-syn), incluyendo, pero no limitados a, cuerpos de Lewy y/o neuritas de Lewy, tal como la enfermedad de Parkinson, atrofia multisistémica, demencia con cuerpos de Lewy (LBD; demencia con cuerpos de Lewy (DLB) (demencia con cuerpos de Lewy "pura"), demencia por enfermedad de Parkinson (PDD)) o enfermedad difusa con cuerpos de Lewy. La invención se refiere a moléculas de unión a alfa-sinucleína, en particular a anticuerpos de alfa-sinucleína o un fragmento de unión a antígeno o un derivado de los mismos y a usos de los mismos. Las presentes moléculas también se pueden usar para determinar una predisposición a dicho trastorno, enfermedad o anomalía, monitorear el trastorno, enfermedad o anomalía residual, o predecir la capacidad de respuesta de un paciente que padezca tal trastorno, enfermedad o anomalía al tratamiento con un determinado medicamento.
MX2021012608A 2019-04-18 2020-04-17 Nuevas moleculas para terapia y diagnostico. MX2021012608A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19170207 2019-04-18
EP19207105 2019-11-05
EP20165055 2020-03-23
PCT/EP2020/060898 WO2020212593A1 (en) 2019-04-18 2020-04-17 Novel molecules for therapy and diagnosis

Publications (1)

Publication Number Publication Date
MX2021012608A true MX2021012608A (es) 2021-11-12

Family

ID=70285703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012608A MX2021012608A (es) 2019-04-18 2020-04-17 Nuevas moleculas para terapia y diagnostico.

Country Status (10)

Country Link
US (1) US20220298231A1 (es)
EP (1) EP3956027A1 (es)
JP (1) JP2022529344A (es)
KR (1) KR20210154179A (es)
CN (1) CN114206444A (es)
AU (1) AU2020258025A1 (es)
CA (1) CA3133909A1 (es)
MX (1) MX2021012608A (es)
TW (1) TW202104255A (es)
WO (1) WO2020212593A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
TW202306966A (zh) * 2021-06-18 2023-02-16 日商住友製藥股份有限公司 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
CA2325346A1 (en) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
US20050147989A1 (en) * 2003-10-02 2005-07-07 Uwe Bertsch Screening assay for aggregations
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2865597A1 (en) 2012-03-16 2013-09-19 Covagen Ag Novel binding molecules with antitumoral activity
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2017272804B2 (en) 2016-06-02 2023-11-23 Medimmune Limited Antibodies to alpha-synuclein and uses thereof
MA46836A (fr) * 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
BR112018016717A2 (pt) * 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
WO2019040617A1 (en) * 2017-08-23 2019-02-28 The Trustees Of The University Of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME

Also Published As

Publication number Publication date
EP3956027A1 (en) 2022-02-23
KR20210154179A (ko) 2021-12-20
CN114206444A (zh) 2022-03-18
TW202104255A (zh) 2021-02-01
JP2022529344A (ja) 2022-06-21
CA3133909A1 (en) 2020-10-22
WO2020212593A1 (en) 2020-10-22
US20220298231A1 (en) 2022-09-22
AU2020258025A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2021012608A (es) Nuevas moleculas para terapia y diagnostico.
MX2018010693A (es) Compuestos biciclicos para diagnostico y terapia.
Woo et al. Chronic restraint stress induces hippocampal memory deficits by impairing insulin signaling
Li et al. Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder
Li et al. Electroacupuncture decreases cognitive impairment and promotes neurogenesis in the APP/PS1 transgenic mice
MX2020012932A (es) Nuevos compuestos para diagnostico.
MX2011010353A (es) Composicion farmaceutica.
Sharma et al. Co-administration of TiO2 nanowired mesenchymal stem cells with cerebrolysin potentiates neprilysin level and reduces brain pathology in Alzheimer’s disease
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX338421B (es) Anticuerpos fosfoespecificos que reconocen la proteina tau.
MX2018000696A (es) Anticuerpos humanizados anti-beta-amiloide piroglutamados.
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
MX2018016066A (es) Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos.
MX2022006676A (es) Nuevas moleculas para terapia y diagnostico.
EP3740761A4 (en) ACCOMPANYING DIAGNOSTICS FOR NSAIDS AND DONEPEZIL FOR THE TREATMENT OF SPECIFIC SUBPOPULATIONS OF PATIENTS WITH ALZHEIMER'S MORBUS
Jang et al. Seizure-induced regulations of amyloid-β, STEP 61, and STEP 61 substrates involved in hippocampal synaptic plasticity
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
PH12012501882A1 (en) Humanized antibody against amyloid beta
AR118788A1 (es) Moléculas para terapia y diagnóstico
MX2023010625A (es) Anticuerpos anti-beta amiloide y usos de estos.
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
Jo et al. Lipocalin-2 secreted by the liver regulates neuronal cell function through AKT-dependent signaling in hepatic encephalopathy mouse model
EA202091629A1 (ru) Гуманизированные и деиммунизированные антитела